The European Commission has extended its approval of Johnson & Johnson’s Darzalex (daratumumab) for injection under the skin as part of a quadruple regimen…
News
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
PANCREATIC CANCER
Immunotherapy implant promising for treating pancreatic cancers
A new approach in immunotherapy that can safely boost the body’s immune response has shown promise in hard-to-treat tumors like pancreatic cancers, a study…
Personalized dosing and monitoring of drug levels may be necessary for children with low-grade glioma treated with Mekinist (trametinib), according to a study. The…
Getting regular exercise can help improve life quality, ease depression, and minimize the risk of medication side effects in people with newly diagnosed multiple…
GYNECOLOGICAL CANCER
Trial to test relacorilant combo in platinum-resistant ovarian cancer
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with…
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…
PANCREATIC CANCER
Blocking FGFR2 may stop pancreatic cancer from developing
Blocking the activity of a protein called FGFR2 may prevent some pancreatic cancers from developing, a study in mice indicated. The study, “…
CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…
GYNECOLOGICAL CANCER
Trial: Relacorilant aids survival in platinum-resistant ovarian cancer
Adding relacorilant to standard chemotherapy was shown to extend survival among people with platinum-resistant ovarian cancer, meeting the primary endpoint, or goal, of a…
Recent Posts
- The parallel calendars: Living between treatment cycles and ordinary days
- First participant receives GLIX1 in early glioblastoma clinical trial
- World Ovarian Cancer Day campaign spotlights scars seen and unseen
- Gilead completes Arcellx buy, securing myeloma treatment anito-cel
- Why the answer to ‘Should I call the doctor?’ is always yes
